Higher cancer risk seen in cardiovascular-kidney-metabolic syndrome; experts recommend precautions
May 4, 2026 / CKM syndrome / Cancer risk / Metabolic disease / Cardiovascular health / Chronic conditions
Cardiovascular-kidney-metabolic (CKM) syndrome is linked to up to 30% higher cancer risk, with severity correlating to risk, highlighting the need for integrated screening and management of metabolic, cardiovascular, and renal health to prevent malignancy.
Grant Supports Early-Career Research on Metabolism and Dietary Choices
May 4, 2026 / Obesity research / Insulin resistance / Brain reward system / Eating behavior / Metabolic health
NIH-funded research explores how obesity and insulin resistance alter brain reward circuits and decision-making, revealing metabolic influences on eating behavior and offering insights into neurobiological drivers of diet-related choices and metabolic disease risk.
Your oral microbiome could affect your weight, liver and diabetes risk
April 30, 2026 / Oral microbiome / Metabolic health / Obesity risk / Fatty liver disease / Diabetes screening
Large-scale research links oral microbiome composition to obesity, prediabetes, and fatty liver disease risk, suggesting oral microbial profiles may serve as noninvasive biomarkers for systemic metabolic health and multi-organ disease screening.
GLP-1 weight-loss drugs may cause metabolic imbalance, study finds
April 30, 2026 / GLP-1 therapy / Metabolic instability / Muscle loss / Nutrient deficiency / Obesity treatment
Prolonged GLP-1 therapy may induce systemic metabolic instability, with muscle loss, nutrient deficiencies, and oxidative stress driven by chronic energy restriction, highlighting the need for integrated monitoring of muscle mass, micronutrients, and metabolic biomarkers during obesity treatment.
Boehringer’s dual agonist obesity drug spurs up to 16.6% weight loss
April 28, 2026 / Dual agonist / Obesity drug / Weight loss / Lean mass preservation / Cardiometabolic health
Boehringer’s dual GLP-1/glucagon agonist survodutide achieved up to 16.6% weight loss in phase 3 trials, with potential advantages in preserving lean mass and improving cardiometabolic and liver outcomes, addressing key limitations of current obesity therapies.
New research shows weight loss is possible without GLP-1
April 30, 2026 / GLP-1 alternatives / Dual agonist / Obesity treatment / GIP glucagon / Weight loss therapy
Preclinical research suggests GLP-1 activity may not be essential for weight loss, with glucagon/GIP dual agonism achieving comparable efficacy while potentially reducing gastrointestinal side effects, supporting development of more tolerable, patient-centric obesity therapies.
Study finds bariatric surgery less costly than GLP-1 drugs over time
May 5, 2026 / Bariatric surgery / GLP-1 drugs / Obesity treatment / Healthcare costs / Type 2 diabetes
Real-world data show bariatric surgery is more cost-effective than GLP-1 therapies over two years in patients with obesity and type 2 diabetes, offering more durable clinical outcomes and lower total healthcare costs despite higher upfront intervention.
Turning white fat brown: How electroacupuncture reprograms obese metabolism
April 28, 2026 / Electroacupuncture / Fat browning / Thermogenesis / Obesity treatment / Metabolic regulation
Electroacupuncture promotes browning of white adipose tissue via PKA/CREB signaling, enhancing thermogenesis, improving lipid metabolism, and reducing weight in obese models, highlighting a non-pharmacologic strategy to reprogram energy balance and metabolic health.
Active brown fat may protect heart health in obese individuals
May 4, 2026 / Brown fat / Vascular inflammation / Obesity risk / Cardiovascular health / Atherosclerosis
Active brown adipose tissue in obese individuals is associated with reduced vascular inflammation and improved cardiometabolic profiles, suggesting a protective role against atherosclerosis and cardiovascular risk through anti-inflammatory and energy-expending mechanisms.
Dual-Agonist Survodutide Shows Significant Weight Loss in Phase III Obesity Trial
April 28, 2026 / Survodutide / Dual agonist / Weight loss / Cardiometabolic risk / GLP-1 therapy
Phase III data show survodutide delivers significant fat-weight loss and waist reduction, with potential cardiometabolic and hepatic benefits via GLP-1/glucagon mechanisms, while maintaining tolerability consistent with existing incretin-based therapies across obesity and related disease populations.
Why Metabolic Health Is a Common Thread Across Diabetes, Heart Disease, and Some Cancer
May 1, 2026 / Metabolic health / Insulin resistance / Chronic inflammation / Cardiometabolic disease / Cancer risk
Metabolic dysfunction, driven by insulin resistance, abnormal fat storage, and chronic inflammation, underpins diabetes, cardiovascular, kidney, liver diseases, and some cancers, with dietary interventions targeting glucose and insulin regulation offering potential reversal across these interconnected conditions.
Grant backs early-career study on metabolism and food choices
April 30, 2026 / Metabolism brain / Insulin resistance / Eating behavior / Neuroimaging research / Obesity treatment
NIH-funded research will examine how obesity and insulin resistance alter brain reward pathways and decision-making, using neuroimaging and computational modeling to better understand how metabolic signals influence eating behavior and inform personalized obesity treatments.
One molecule, two effects: A new drug concept to treat obesity and type 2 diabetes
April 29, 2026 / Hybrid therapy / GLP-1 GIP / PPAR agonist / Obesity diabetes / Targeted metabolism
A novel “Trojan horse” hybrid drug combining GLP-1/GIP agonism with targeted PPAR modulation improved weight loss, glycemic control, and insulin sensitivity in preclinical models, suggesting a more precise, lower-toxicity approach to treating obesity and type 2 diabetes.
Bariatric surgery improves outcomes for patients with obesity and chronic kidney disease
May 5, 2026 / Bariatric surgery / Chronic kidney disease / Cardiovascular risk / Obesity treatment / Mortality reduction
Bariatric surgery significantly improves outcomes in obese patients with chronic kidney disease, reducing risks of kidney failure, cardiovascular events, and mortality while increasing transplant likelihood, highlighting its role as a disease-modifying intervention beyond weight loss.
Viking Therapeutics Announces Two Poster Presentations at European Congress on Obesity (ECO) 2026
May 5, 2025 / VK2735 / GLP-1 GIP / Obesity therapy / Clinical trials / Metabolic disease
Viking Therapeutics will present Phase 2 efficacy and safety data and Phase 3 trial design for its dual GLP-1/GIP agonist VK2735, advancing both oral and injectable formulations for obesity and metabolic disease treatment.
Surprising obesity discovery rewrites decades of fat metabolism science
April 30, 2026 / Fat metabolism / Adipose tissue / Obesity research / Metabolic dysfunction / Protein regulation
New research reveals a key fat metabolism protein also preserves adipose tissue function; its disruption drives metabolic imbalance, reframing obesity as a disorder of adipose tissue dysfunction rather than simply excess fat accumulation.
Noninvasive Tests Key to Identifying MASH in Primary Care
April 30, 2026 / MASH screening / Noninvasive testing / Liver disease / Obesity diabetes / Primary care
Noninvasive testing enables early identification and management of MASH in primary care, supporting timely intervention through lifestyle changes and medications, particularly in patients with obesity and diabetes where disease is often asymptomatic until advanced stages.
New kind of liver cell identified may protect against common liver disease
May 4, 2026 / MASH liver disease / Hepatocytes / Cellular senescence / Liver inflammation / Metabolic disease
Researchers identified a novel senescent hepatocyte subtype in MASH that may influence inflammation and disease progression, revealing new cellular mechanisms and potential therapeutic targets for metabolic liver disease.
Madrigal picks up another siRNA asset for MASH, betting up to $1B with Arrowhead
May 5, 2025 / MASH therapy / siRNA treatment / PNPLA3 mutation / Liver fat reduction / Precision medicine
Madrigal licensed an siRNA therapy targeting PNPLA3 mutations in MASH, showing significant liver fat reduction in early studies, expanding its precision medicine pipeline to complement existing therapies and address genetic drivers of disease progression.